HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
GILD
Gilead Sciences Inc
Healthcare Drug Manufacturers - General · California, USA · Reports in usd
Market Cap: $169.10B
Market Cap
$169.10B
Enterprise Val
$186.41B
P/E Ratio
19.87
P/B Ratio
7.45
Trailing PEG (1Y)
0.83
As Of
May 5, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$22.62B
Gross Margin79.51%
Profit Margin79.51%
Return on Equity40.97%
Return on Assets14.82%
Current Ratio1.55
Debt/Equity1.10
LT Debt/Equity0.97
Revenue Per Share6.39

Income Statement

Dec 31, 2025
Revenue$7.93B
Cost of Revenue$1.62B
Gross Profit$6.30B
R&D$1.58B
SG&A$1.79B
Operating Expenses$4.32B
Operating Income$1.98B
Interest Expense$255.0M
Tax Expense-$105.0M
Net Income$2.18B
EPS (Basic)$1.76
EPS (Diluted)$1.74
EBIT$2.33B
EBITDA$3.02B
Consolidated Income$2.18B
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$7.56B
Accounts Receivable$4.91B
Inventory$1.77B
Current Assets$18.34B
LT Investments$2.97B
Property, Plant & Equipment$5.61B
Intangibles$25.29B
Non-Current Assets$40.68B
Total Assets$59.02B
Accounts Payable$715.0M
Current Debt$2.81B
Current Liabilities$11.81B
LT Debt$22.13B
Non-Current Liabilities$24.59B
Total Liabilities$36.41B
Total Debt$24.94B
Retained Earnings$13.73B
Shareholder Equity$22.70B
Shares Outstanding1,240,679,623

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$3.33B
Investing Cash Flow-$1.84B
Financing Cash Flow-$1.26B
CapEx-$205.0M
Free Cash Flow$3.12B
Depreciation & Amort.$687.0M
Stock-Based Comp$230.0M
Acquisitions / Disposals-$609.0M
Investment Activity-$1.03B
Debt Issued/Repaid-$8.0M
Equity Issued/Repaid-$198.0M
Dividends Paid-$994.0M
Net Change in Cash$233.0M
Data cached · Meta live · Daily live · Statements live · TTL 24h